Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.
Authors
Yali Shen
West China Hospital Sichuan University, Chengdu, China
Yali Shen , Feng Wen , Peng Zhang , Tianhai Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 499)
DOI
10.1200/JCO.2022.40.6_suppl.499
Abstract #
499
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
First Author: Xin-Gang Bi
Poster
2024 ASCO Genitourinary Cancers Symposium
Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.
First Author: Yu Zeng
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC).
First Author: Andrew B Katims
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
First Author: Ali Raza Khaki